PH12018501694B1 - Tetrahydroisoquinoline derivatives - Google Patents
Tetrahydroisoquinoline derivativesInfo
- Publication number
- PH12018501694B1 PH12018501694B1 PH1/2018/501694A PH12018501694A PH12018501694B1 PH 12018501694 B1 PH12018501694 B1 PH 12018501694B1 PH 12018501694 A PH12018501694 A PH 12018501694A PH 12018501694 B1 PH12018501694 B1 PH 12018501694B1
- Authority
- PH
- Philippines
- Prior art keywords
- muscle
- troponin
- disorders
- modulation
- treating
- Prior art date
Links
- 125000003039 tetrahydroisoquinolinyl group Chemical class C1(NCCC2=CC=CC=C12)* 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 208000035475 disorder Diseases 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 210000002235 sarcomere Anatomy 0.000 abstract 2
- -1 tetrahydroisoquinoline derivative compounds Chemical class 0.000 abstract 2
- 102000007469 Actins Human genes 0.000 abstract 1
- 108010085238 Actins Proteins 0.000 abstract 1
- 108090000362 Lymphotoxin-beta Proteins 0.000 abstract 1
- 208000010428 Muscle Weakness Diseases 0.000 abstract 1
- 206010028289 Muscle atrophy Diseases 0.000 abstract 1
- 206010049565 Muscle fatigue Diseases 0.000 abstract 1
- 206010028372 Muscular weakness Diseases 0.000 abstract 1
- 102000003505 Myosin Human genes 0.000 abstract 1
- 108060008487 Myosin Proteins 0.000 abstract 1
- 102000001708 Protein Isoforms Human genes 0.000 abstract 1
- 108010029485 Protein Isoforms Proteins 0.000 abstract 1
- 102000005937 Tropomyosin Human genes 0.000 abstract 1
- 108010030743 Tropomyosin Proteins 0.000 abstract 1
- 102000004903 Troponin Human genes 0.000 abstract 1
- 108090001027 Troponin Proteins 0.000 abstract 1
- 102000013534 Troponin C Human genes 0.000 abstract 1
- 102000013394 Troponin I Human genes 0.000 abstract 1
- 108010065729 Troponin I Proteins 0.000 abstract 1
- 102000004987 Troponin T Human genes 0.000 abstract 1
- 108090001108 Troponin T Proteins 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000037444 atrophy Effects 0.000 abstract 1
- 208000015114 central nervous system disease Diseases 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 230000004064 dysfunction Effects 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 210000003205 muscle Anatomy 0.000 abstract 1
- 208000016334 muscle symptom Diseases 0.000 abstract 1
- 201000000585 muscular atrophy Diseases 0.000 abstract 1
- 208000018360 neuromuscular disease Diseases 0.000 abstract 1
- 210000003903 pelvic floor Anatomy 0.000 abstract 1
- 210000002027 skeletal muscle Anatomy 0.000 abstract 1
- 210000005070 sphincter Anatomy 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- 230000009885 systemic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/24—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0658—Skeletal muscle cells, e.g. myocytes, myotubes, myoblasts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
- C12N2509/10—Mechanical dissociation
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Heart & Thoracic Surgery (AREA)
- Wood Science & Technology (AREA)
- Rheumatology (AREA)
- Zoology (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Child & Adolescent Psychology (AREA)
- Cell Biology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662285039P | 2016-02-12 | 2016-02-12 | |
| PCT/US2017/017295 WO2017139526A1 (en) | 2016-02-12 | 2017-02-10 | Tetrahydroisoquinoline derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| PH12018501694A1 PH12018501694A1 (en) | 2019-01-28 |
| PH12018501694B1 true PH12018501694B1 (en) | 2023-08-30 |
Family
ID=59561239
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH1/2018/501694A PH12018501694B1 (en) | 2016-02-12 | 2017-02-10 | Tetrahydroisoquinoline derivatives |
Country Status (34)
| Country | Link |
|---|---|
| US (5) | US9914741B2 (https=) |
| EP (2) | EP4032877A1 (https=) |
| JP (2) | JP6832943B2 (https=) |
| KR (1) | KR20180120701A (https=) |
| CN (2) | CN109069498B (https=) |
| AR (1) | AR107592A1 (https=) |
| AU (1) | AU2017217663B2 (https=) |
| BR (1) | BR112018016475A2 (https=) |
| CA (1) | CA3012839A1 (https=) |
| CL (1) | CL2018002287A1 (https=) |
| CO (1) | CO2018007920A2 (https=) |
| CY (1) | CY1125222T1 (https=) |
| DK (1) | DK3413892T3 (https=) |
| ES (1) | ES2913423T3 (https=) |
| HR (1) | HRP20220655T1 (https=) |
| HU (1) | HUE058820T2 (https=) |
| IL (1) | IL261055B (https=) |
| LT (1) | LT3413892T (https=) |
| MA (1) | MA44018B1 (https=) |
| MD (1) | MD3413892T2 (https=) |
| MX (1) | MX379159B (https=) |
| NZ (1) | NZ746311A (https=) |
| PH (1) | PH12018501694B1 (https=) |
| PL (1) | PL3413892T3 (https=) |
| PT (1) | PT3413892T (https=) |
| RS (1) | RS63240B1 (https=) |
| RU (1) | RU2743424C2 (https=) |
| SG (1) | SG11201806416XA (https=) |
| SI (1) | SI3413892T1 (https=) |
| SM (1) | SMT202200201T1 (https=) |
| TW (2) | TWI773118B (https=) |
| UA (1) | UA124879C2 (https=) |
| WO (1) | WO2017139526A1 (https=) |
| ZA (1) | ZA201804947B (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112018016475A2 (en) * | 2016-02-12 | 2018-12-26 | Cytokinetics, Incorporated | tetrahydroisoquinoline derivatives |
| GB201905721D0 (en) | 2019-04-24 | 2019-06-05 | Univ Dundee | Compounds |
| WO2022099011A1 (en) * | 2020-11-06 | 2022-05-12 | Cytokinetics, Inc. | Bicyclic 1,4-diazepanones and therapeutic uses thereof |
| WO2025080100A1 (ko) * | 2023-10-11 | 2025-04-17 | 한국화학연구원 | 신규한 디-아미드 화합물, 이의 제조방법, 이를 유효성분으로 포함하는 암 또는 자가면역질환의 예방 또는 치료용 약학적 조성물 |
| CN117379425A (zh) * | 2023-11-14 | 2024-01-12 | 广州日聚商贸发展有限公司 | 喹啉-4-羧酸在抗衰老产品以及保护肝脏、促进肝脏再生产品制备中的应用 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3301857A (en) | 1963-08-26 | 1967-01-31 | Hoffmann La Roche | Spiro |
| SE368009B (https=) | 1971-09-16 | 1974-06-17 | Kabi Ab | |
| US6492520B1 (en) * | 1996-08-06 | 2002-12-10 | Pfizer Inc | Substituted pyrido-or pyrimido-containing 6,6- or 6,7-bicyclic derivatives |
| KR100567649B1 (ko) | 1996-09-25 | 2006-04-05 | 아스트라제네카 유케이 리미티드 | 혈관 내피 성장 인자와 같은 성장 인자의 효과를 억제하는 퀴놀린 유도체 |
| US6410254B1 (en) | 1999-05-18 | 2002-06-25 | Cytokinetics | Compositions and assays utilizing ADP or phosphate for detecting protein modulators |
| US6743599B1 (en) | 1999-05-18 | 2004-06-01 | Cytokinetics, Inc. | Compositions and assays utilizing ADP or phosphate for detecting protein modulators |
| US7202051B1 (en) | 1999-05-18 | 2007-04-10 | Cytokinetics, Inc. | Compositions and assays utilizing ADP or phosphate for detecting protein modulators |
| US6958333B1 (en) * | 1999-07-26 | 2005-10-25 | Banyu Pharmaceutical Co., Ltd. | Biarylurea derivatives |
| JP2001106673A (ja) * | 1999-07-26 | 2001-04-17 | Banyu Pharmaceut Co Ltd | ビアリールウレア誘導体 |
| GB0321538D0 (en) | 2003-09-13 | 2003-10-15 | Glaxo Group Ltd | Therapeutically useful compounds |
| JP4361566B2 (ja) * | 2004-04-28 | 2009-11-11 | 武田薬品工業株式会社 | 縮合キノリン誘導体およびその使用 |
| WO2007075783A2 (en) * | 2005-12-22 | 2007-07-05 | Wyeth | Substituted isoquinoline-1,3(2h,4h)-diones, 1-thioxo-1,4-dihydro-2h-isoquinoline-3-ones and 1,4-dihydro-3(2h)-isoquinolones and use thereof as kinase inhibitor |
| GB0613208D0 (en) | 2006-07-03 | 2006-08-09 | Glaxo Group Ltd | Compounds |
| ES2558517T3 (es) | 2006-08-02 | 2016-02-04 | Cytokinetics, Inc. | Ciertas entidades químicas, composiciones y métodos que comprenden imidazopirimidinas |
| NZ577980A (en) * | 2006-12-27 | 2012-01-12 | Sanofi Aventis | Cycloalkylamine substituted isoquinolone derivatives |
| RU2443698C2 (ru) | 2007-01-05 | 2012-02-27 | Дайити Санкио Компани, Лимитед | Конденсированное замещенное производное аминопирролидина |
| US8163909B2 (en) | 2007-05-25 | 2012-04-24 | Amgen Inc. | Substituted hydroxyethyl amine compounds as beta-secretase modulators and methods of use |
| JP5451646B2 (ja) * | 2008-02-27 | 2014-03-26 | ヴァイティー ファーマシューティカルズ，インコーポレイテッド | １１β−ヒドロキシステロイドデヒドロゲナーゼ１型の阻害剤 |
| CN101518971B (zh) * | 2008-02-29 | 2012-07-18 | E.I.内穆尔杜邦公司 | 聚酯叠层膜和使用该叠层膜的太阳能电池板 |
| NZ592008A (en) * | 2008-10-02 | 2011-12-22 | Taisho Pharmaceutical Co Ltd | 7-piperidinoalkyl-3,4-dihydroquinolone derivative |
| CN102256493A (zh) | 2008-10-29 | 2011-11-23 | 迪赛孚尔制药有限公司 | 表现出抗癌活性和抗增殖活性的环丙烷酰胺及其类似物 |
| WO2010131145A1 (en) | 2009-05-12 | 2010-11-18 | Pfizer Limited | Cyclobutenedione derivatives |
| US9133123B2 (en) | 2010-04-23 | 2015-09-15 | Cytokinetics, Inc. | Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use |
| AR081331A1 (es) | 2010-04-23 | 2012-08-08 | Cytokinetics Inc | Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos |
| AR081626A1 (es) | 2010-04-23 | 2012-10-10 | Cytokinetics Inc | Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos |
| US8933072B2 (en) | 2010-06-16 | 2015-01-13 | Vitae Pharmaceuticals, Inc. | Substituted 5-,6- and 7-membered heterocycles, medicaments containing such compounds, and their use |
| CN103476757A (zh) * | 2011-02-18 | 2013-12-25 | 阿勒根公司 | 作为磷酸二酯酶10(pde10a)的抑制剂的取代的6,7-二烷氧基-3-异喹啉醇衍生物 |
| US8759380B2 (en) | 2011-04-22 | 2014-06-24 | Cytokinetics, Inc. | Certain heterocycles, compositions thereof, and methods for their use |
| HUP1100241A3 (en) | 2011-05-06 | 2013-12-30 | Richter Gedeon Nyrt | Oxetane substituted pyrimidones |
| SG10201701101YA (en) | 2012-04-02 | 2017-04-27 | Cytokinetics Inc | Methods for improving diaphragm function |
| CN111840294A (zh) | 2012-04-11 | 2020-10-30 | 赛特凯恩蒂克公司 | 改善对骨骼肌疲劳的抵抗力的方法 |
| AR091699A1 (es) * | 2012-07-10 | 2015-02-25 | Astellas Pharma Inc | Derivado de indol carboxamida |
| HUE057533T2 (hu) | 2014-04-29 | 2022-05-28 | Cytokinetics Inc | Eljárások vitálkapacitás csökkenésének gátlására |
| JP6573618B2 (ja) | 2014-09-09 | 2019-09-11 | アステラス製薬株式会社 | 尿失禁予防用及び／又は治療用新規医薬組成物 |
| BR112018016475A2 (en) * | 2016-02-12 | 2018-12-26 | Cytokinetics, Incorporated | tetrahydroisoquinoline derivatives |
-
2017
- 2017-02-10 BR BR112018016475-5A patent/BR112018016475A2/en not_active IP Right Cessation
- 2017-02-10 US US15/429,738 patent/US9914741B2/en active Active
- 2017-02-10 MX MX2018009759A patent/MX379159B/es unknown
- 2017-02-10 DK DK17750801.7T patent/DK3413892T3/da active
- 2017-02-10 JP JP2018541693A patent/JP6832943B2/ja not_active Expired - Fee Related
- 2017-02-10 NZ NZ746311A patent/NZ746311A/en not_active IP Right Cessation
- 2017-02-10 EP EP22160176.8A patent/EP4032877A1/en not_active Withdrawn
- 2017-02-10 KR KR1020187026486A patent/KR20180120701A/ko not_active Withdrawn
- 2017-02-10 PL PL17750801T patent/PL3413892T3/pl unknown
- 2017-02-10 UA UAA201809258A patent/UA124879C2/uk unknown
- 2017-02-10 LT LTEPPCT/US2017/017295T patent/LT3413892T/lt unknown
- 2017-02-10 HU HUE17750801A patent/HUE058820T2/hu unknown
- 2017-02-10 SI SI201731142T patent/SI3413892T1/sl unknown
- 2017-02-10 ES ES17750801T patent/ES2913423T3/es active Active
- 2017-02-10 EP EP17750801.7A patent/EP3413892B1/en active Active
- 2017-02-10 TW TW110103986A patent/TWI773118B/zh not_active IP Right Cessation
- 2017-02-10 HR HRP20220655TT patent/HRP20220655T1/hr unknown
- 2017-02-10 MA MA44018A patent/MA44018B1/fr unknown
- 2017-02-10 PT PT177508017T patent/PT3413892T/pt unknown
- 2017-02-10 SG SG11201806416XA patent/SG11201806416XA/en unknown
- 2017-02-10 CN CN201780010949.1A patent/CN109069498B/zh not_active Expired - Fee Related
- 2017-02-10 CN CN202110837700.6A patent/CN113666938A/zh active Pending
- 2017-02-10 SM SM20220201T patent/SMT202200201T1/it unknown
- 2017-02-10 CA CA3012839A patent/CA3012839A1/en active Pending
- 2017-02-10 AR ARP170100336A patent/AR107592A1/es unknown
- 2017-02-10 AU AU2017217663A patent/AU2017217663B2/en not_active Ceased
- 2017-02-10 TW TW106104493A patent/TWI719138B/zh not_active IP Right Cessation
- 2017-02-10 WO PCT/US2017/017295 patent/WO2017139526A1/en not_active Ceased
- 2017-02-10 PH PH1/2018/501694A patent/PH12018501694B1/en unknown
- 2017-02-10 RS RS20220483A patent/RS63240B1/sr unknown
- 2017-02-10 MD MDE20181214T patent/MD3413892T2/ro unknown
- 2017-02-10 RU RU2018130002A patent/RU2743424C2/ru active
-
2018
- 2018-01-17 US US15/873,571 patent/US10259821B2/en active Active
- 2018-07-23 ZA ZA2018/04947A patent/ZA201804947B/en unknown
- 2018-07-30 CO CONC2018/0007920A patent/CO2018007920A2/es unknown
- 2018-08-08 IL IL261055A patent/IL261055B/en active IP Right Grant
- 2018-08-10 CL CL2018002287A patent/CL2018002287A1/es unknown
-
2019
- 2019-03-04 US US16/291,481 patent/US10689393B2/en active Active
-
2020
- 2020-05-11 US US16/871,532 patent/US11479561B2/en active Active
-
2021
- 2021-02-01 JP JP2021014223A patent/JP7137650B2/ja active Active
-
2022
- 2022-06-03 CY CY20221100392T patent/CY1125222T1/el unknown
- 2022-09-13 US US17/944,060 patent/US20230125280A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201804947B (en) | Tetrahydroisoquinoline derivatives | |
| PH12020551927A1 (en) | Tetrahydro-imidazo[4,5-c]pyridine derivatives as pd-l1 immunomodulators | |
| MY199046A (en) | 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors | |
| PH12020551572A1 (en) | Heterocyclic compounds as immunomodulators | |
| ZA202100208B (en) | Heterocyclic and heteroaryl compounds for treating huntington's disease | |
| WO2009087212A3 (en) | Pyridine derivatives | |
| IS2916B (is) | P38 kínasatálmar að stofni til úr 5 hluta heteróhring | |
| CR20210544A (es) | DERIVADOS DE 1,1-DIÓXIDO DE 3-AMINO-4H-BENZO[E][1,2,4] tiadiazina COMO INHIBIDORES DE MRGX2 | |
| EA201890318A1 (ru) | СОЕДИНЕНИЯ ЗАМЕЩЕННОГО ПИРАЗОЛО[1,5-a]ПИРИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ RET КИНАЗЫ | |
| WO2009050183A3 (en) | Imidazo [1, 2-a] pyridine derivatives useful as alk inhibitors | |
| MY187552A (en) | Pharmaceutical compositions comprising an integrin alpha4 antagonist for use in treating ocular inflammatory conditions | |
| ATE478865T1 (de) | Selektive rock-proteinkinasehemmer und ihre verwendung | |
| EP4553065A3 (en) | Novel compounds for treating mitochondrial disease | |
| EP4520395A3 (en) | Tricyclic janus kinase 1 inhibitors, and compositions and methods thereof | |
| WO2017177004A8 (en) | Tertiary amides and method of use | |
| WO2018160879A3 (en) | Macromolecular corrosion (mcin) inhibitors: structures, methods of making and using the same | |
| EA202091804A1 (ru) | Гетероциклил-замещенные оксадиазолопиридиновые производные для применения в качестве ингибиторов грелин-о-ацилтрансферазы (goat) | |
| PH12020551071A1 (en) | Compositions and methods for treating retinal disorders | |
| JOP20200012A1 (ar) | تركيبة للاستخدام في الوقاية من مَرَضِيَّات جهاز القلبي الوعائي ومعالجتها | |
| EP3412276A3 (de) | Zusammensetzung zur behandlung des trockenen auges | |
| MX2021006867A (es) | Glutarato de 3-(1,2,3,6-tetrahidropiridin-2-il)piridina o un solvato farmaceuticamente aceptable del mismo. | |
| MX2023005408A (es) | Compuestos y su uso en el tratamiento de trastornos mediados por el receptor de taquiquinina. | |
| WO2019143831A8 (en) | Compositions and methods for increasing expression of scn2a | |
| WO2015070076A3 (en) | Methods and compositions for rejuvenating neuromuscular junctions | |
| AU2018279977A1 (en) | Natural and organic binder compositions for oral solid dosage forms |